GBA1 and Parkinson disease: The results of the first open-label clinical trial of ambroxol in PD patients with and withoutGBA1 mutations (AiM-PD) have recently been published, where the drug was found to be well tolerated over 6 months, with an associated rise in CSF glucocerebrosidase levels57.